Current understanding of cancer-intrinsic PD-L1: regulation of expression and its protumoral activity

키워드

참고문헌 (76)

1. Chen L, "Molecular mechanisms of T cell co-stimulation and co-inhibition", Nat Rev Immunol, 13, pp.227~242 (2013)
2. Cai J, "The role of PD-1", PD-L1 axis in treg development and function : impli-cations for cancer immunotherapy, 2019, pp.12, 8437~8445
3. Xin Yu J, "Trends in clinical develop-ment for PD-1", PD-L1 inhibitors, 2020, pp.19, 163~164
4. Sun L, "Clinical efficacy and safety of anti-PD-1", PD-L1 inhibitors for the treatment of advanced or metastatic cancer : a systematic review and meta-analysis, 2020, pp.10, 2083~
5. Azuma T, "B7-H1 is a ubiquitous antiapoptotic receptor on cancer cells", Blood, 111, pp.3635~3643 (2008)
6. Yu W, "PD-L1 promotes tumor growth and progression by activating WIP and beta-cate-nin signaling pathways and predicts poor prognosis in lung cancer", Cell Death Dis, 11, pp.506~ (2020)
7. Lee S-J, "Interferon regu-latory factor-1 is prerequisite to the constitutive expression and IFN-γ-induced upregulation of B7-H1(CD274)", FEBS Lett, 580, pp.755~762 (2006)
8. Cancer Genome Atlas Research Network, "Integrated genomic and molecular characterization of cervical cancer", Nature, 543, pp.378~384 (2017)
9. Steidl C, "MHC class II transactivator CIITA is a recurrent gene fusion partner in lymphoid cancers", Nature, 471, pp.377~381 (2011)
10. Kataoka K, "Aberrant PD-L1 expression through 3’-UTR disruption in multiple cancers", Nature, 534, pp.402~406 (2016)
11. Wu Y, "Polymorphism of the programmed death‐ligand 1 gene is associated with its pro-tein expression and prognosis in gastric cancer", J Gastro-enterol Hepatol, 34, pp.1201~1207 (2019)
12. Xiao G, "EZH2 negatively regulates PD-L1 expression in hepatocellular carcinoma", J Immunother Cancer, 7, pp.1~15 (2019)
13. Nair VS, "DNA methylation and repressive H3K9 and H3K27 trimethylation in the promoter regions of PD-1, CTLA-4, TIM-3, LAG-3, TIGIT, and PD-L1 genes in human primary breast cancer", Clin Epigenetics, 10, pp.78~ (2018)
14. Lu C, "The MLL1-H3K4me3axis-mediated PD-L1 expression and pancreatic cancer immune evasion", J Natl Cancer Inst, 109, pp.djw283~ (2017)
15. Casey SC, "MYC regulates the antitumor immune response through CD47 and PD-L1", Science, 352, pp.227~231 (2016)
16. Song TL, "Onco-genic activation of the STAT3 pathway drives PD-L1 ex-pression in natural killer", T-cell lymphoma, 2018, pp.132, 1146~1158
17. Ruf M, "PD-L1 expression is regulated by hypoxia inducible factor in clear cell renal cell carcinoma", Int J Cancer, 139, pp.396~403 (2016)
18. Noman MZ, "PD-L1 is a novel direct target of HIF-1α, and its blockade under hypoxia enhanced MDSC-mediated T cell activation", J Exp Med, 211, pp.781~790 (2014)
19. Green MR, "Constitu-tive AP-1 activity and EBV infection induce PD-L1 in Hodg-kin lymphomas and posttransplant lymphoproliferative disorders : implications for targeted therapy", Clin Cancer Res, 18, pp.1611~1618 (2012)
20. Liu J, "Plasma cells from multiple myeloma patients express B7-H1(PD-L1)and increase expression after stimulation with IFN-γ and TLR ligands via a MyD88-, TRAF6-, and MEK-dependent pathway", Blood, 110, pp.296~304 (2007)
21. Stutvoet TS, "MAPK pathway activity plays a key role in PD‐L1 expression of lung adeno-carcinoma cells", J Pathol, 249, pp.52~64 (2019)
22. Coelho MA, "Oncogenic RAS signaling promotes tumor immunoresis-tance by stabilizing PD-L1 mRNA", Immunity, 47, pp.1083~1099 (2017)
23. Hong S, "Upregulation of PD-L1 by EML4-ALK fusion protein mediates the immune escape in ALK positive NSCLC : implication for optional anti-PD-1", PD-L1 immune therapy for ALK-TKIs sensitive and resistant NSCLC patients, 2016, pp.5, e1094598~
24. van Rensburg HJJ, "The Hippo pathway component TAZ promotes immune evasion in human cancer through PD-L1", Cancer Res, 78, pp.1457~1470 (2018)
25. Chen J, "Dissecting the signaling pathways that mediate cancer in PTEN and LKB1double-knockout mice", Sci Signal, 8, pp.pe1~ (2015)
26. Thiem A, "IFN-gamma-induced PD-L1 expression in melanoma depends on p53expression", J Exp Clin Cancer Res, 38, pp.1~15 (2019)
27. Cortez MA, "PDL1regulation by p53 via miR-34", J Natl Cancer Inst, 108, pp.djv303~ (2016)
28. Xu Y-p, "Tumor suppressor TET2promotes cancer immunity and immunotherapy efficacy", J Clin Invest, 129, pp.4316~4331 (2019)
29. Wu A, "Loss of VGLL 4suppresses tumor PD‐L1 expression and immune evasion", EMBO J, 38, pp.e99506~ (2019)
30. Yan Y, "Interferon regulatory factor 1(IRF-1)and IRF-2 regulate PD-L1 expression in hepatocellular carcinoma(HCC)cells", Cancer Immunol Immunother, 69, pp.891~1903 (2020)
31. Dorand RD, "Cdk5 dis-ruption attenuates tumor PD-L1 expression and promotes antitumor immunity", Science, 353, pp.399~403 (2016)
32. Chen L, "Regulating tumor suppres-sor genes : post-translational modifications", Signal Transduct Target Ther, 5, pp.90~ (2020)
33. Wei S, "LncRNA MALAT1 contributes to non-small cell lung cancer progression via modulating miR-200a-3p", programmed death-ligand 1 axis, 2019, pp.33, 2058738419859699~
34. Zhao L, "LncRNA SNHG14", miR-5590-3p, PD-L1 checkpoint, pp.Cell Death Dis, 2019[DOI]
35. Mineo M, "Tumor interferon signaling is regulated by a lncRNA INCR1 tran-scribed from the PD-L1 Locus", Mol Cell, 78, pp.1209~1223 (2020)
36. Li CW, "Glycosylation and stabilization of programmed death ligand-1 suppresses T-cell activity", Nat Commun, 7, pp.12632~ (2016)
37. Chan LC, "IL-6", JAK1 pathway drives PD-L1 Y112 phosphorylation to promote cancer immune evasion, 2019, pp.129, 3324~3338
38. Apriamashvili G, "Loss of ubiquitin ligase STUB1 amplifies IFNγ-R1", JAK1 signaling and sensitizes tumors to IFNγ, 2020
39. Mezzadra R, "Identification of CMTM6 and CMTM4 as PD-L1 protein regulators", Nature, 549, pp.106~110 (2017)
40. Burr ML, "CMTM6maintains the expression of PD-L1 and regulates anti-tumour immunity", Nature, 549, pp.101~105 (2017)
41. Lim SO, "Deubiquitination and stabilization of PD-L1 by CSN5", Cancer Cell, 30, pp.925~939 (2016)
42. Zhang J, "Author correction : cyclin D-CDK4 kinase destabilizes PD-L1 via cullin 3-SPOP to control cancer immune surveillance", Nature, 571, pp.E10~ (2019)
43. Xu J, "Long noncoding RNA MIR17HG promotes colorectal cancer progression via miR-17-5p", Cancer Res, 79, pp.4882~4895 (2019)
44. Zhang M, "LncRNA GATA3-AS1 facilitates tumour progression and immune escape in triple-negative breast cancer through destabilization of GATA3but stabilization of PD-L1", Cell Prolif, 53, pp.e12855~ (2020)
45. Gato-Canas M, "PDL1signals through conserved sequence motifs to overcome interferon-mediated cytotoxicity", Cell Rep, 20, pp.1818~1829 (2017)
46. Dongre A, "New insights into the mechanisms of epithelial-mesenchymal transition and impli-cations for cancer", Nat Rev Mol Cell Biol, 20, pp.69~84 (2019)
47. Cao Y, "B7-H1 overex-pression regulates epithelial-mesenchymal transition and accelerates carcinogenesis in skin", Cancer Res, 71, pp.1235~1243 (2011)
48. Wang Y, "PD-L1 induces epithelial-to-mesenchymal transition via activating SREBP-1c in renal cell carcinoma", Med Oncol, 32, pp.212~ (2015)
49. Qiu XY, "PD-L1 confers glioblastoma multiforme malignancy via Ras binding and Ras", Erk, Biochim Biophys Acta Mol Basis Dis, pp.2018, 1864[DOI]
50. Cui P, "Prognostic signifi-cance of PD-L1 expression and its tumor-intrinsic func-tions in hypopharyngeal squamous cell carcinoma", Cancer Manag Res, 12, pp.5893~5902 (2020)
51. Fei Z, "PD-L1induces epithelial-mesenchymal transition in nasopharyn-geal carcinoma cells through activation of the PI3K", AKT Pathway, 2019, pp.27, 801~807
52. Zhang Y, "The canonical TGF-beta", Smad signalling pathway is involved in PD-L1-in-duced primary resistance to EGFR-TKIs in EGFR-mutant non-small-cell lung cancer, 2019, pp.20, 164~
53. Clark CA, "Tumor-in-trinsic PD-L1 signals regulate cell growth, pathogenesis, and autophagy in ovarian cancer and melanoma", Cancer Res, 76, pp.6964~6974 (2016)
54. Martinez-Outschoorn UE, "Cancer metabolism : a therapeutic perspective", Nat Rev Clin Oncol, 14, pp.11~31 (2017)
55. Chang CH, "Metabolic competition in the tumor microenvironment is a driver of cancer progression", Cell, 162, pp.1229~1241 (2015)
56. Wang S, "Programmed death ligand 1promotes lymph node metastasis and glucose metabolism in cervical cancer by activating integrin beta4", SNAI1, Oncogene, pp.2018, 37[DOI]
57. Kim S, "Programmed cell death ligand-1-mediated enhancement of hexokinase 2 expression is inversely related to T-cell effector gene expression in non-small-cell lung cancer", J Exp Clin Cancer Res, 38, pp.462~ (2019)
58. Lin R, "Fatty acid oxidation controls CD8(+)tissue-resident memory T-cell survival in gastric adenocarcinoma", Cancer Immunol Res, 8, pp.479~492 (2020)
59. Najafi M, "Cancer stem cells(CSCs)in cancer progression and therapy", J Cell Physiol, 234, pp.8381~8395 (2019)
60. Tamai K, "Suppressive expression of CD274 increases tumorigenesis and cancer stem cell phenotypes in cholangiocarcinoma", Cancer Sci, 105, pp.667~674 (2014)
61. Jinesh GG, "Surface PD-L1, E-cadherin, CD24, and VEGFR2 as markers of epithelial cancer stem cells associated with rapid tumorigenesis", Sci Rep, 7, pp.9602~ (2017)
62. Wu Y, "Increased PD-L1 expression in breast and colon cancer stem cells", Clin Exp Pharmacol Physiol, 44, pp.602~604 (2017)
63. Almozyan S, "PD-L1promotes OCT4 and Nanog expression in breast cancer stem cells by sustaining PI3K", AKT pathway activation, 2017, pp.141, 1402~1412
64. Zhang X, "Propofol reduced mammosphere formation of breast cancer stem cells via PD-L1", Nanog in vitro, 2019, pp.2019, 9078209~
65. Wei F, "PD-L1 promotes colorectal cancer stem cell expansion by activating HMGA1-dependent signaling pathways", Cancer Lett, 450, pp.1~13 (2019)
66. Ishibashi M, "Myeloma drug resistance induced by binding of myeloma B7-H1(PD-L1)to PD-1", Cancer Immunol Res, 4, pp.779~788 (2016)
67. Black M, "Activation of the PD-1", PD-L1 immune checkpoint confers tumor cell chemoresistance associated with increased metastasis, 2016, pp.7, 10557~10567
68. Liu S, "PD-1", PD-L1 interac-tion up-regulates MDR1, AKT and MAPK, pp.ERK pathways, Oncotarget[DOI]
69. Feng D, "BRAF(V600E)-induced, tumor intrinsic PD-L1 can regulate chemotherapy-induced apoptosis in human colon cancer cells and in tumor xenografts", Oncogene, 38, pp.6752~6766 (2019)
70. Tu X, "PD-L1(B7-H1)Competes with the RNA exosome to regulate the DNA damage response and can be targeted to sensitize to radiation or chemotherapy", Mol Cell, 74, pp.1215~1226 (2019)
71. Brech A, "Autophagy in tumour suppression and promotion", Mol Oncol, 3, pp.366~375 (2009)
72. Clark CA, "Tumor cell-intrinsic CD274", PD-L1 : a novel metabolic balancing act with clinical potential, 2017, pp.13, 987~988
73. Chen RQ, "The binding of PD-L1and Akt facilitates glioma cell invasion upon starvation via Akt", Autophagy, Front Oncol, pp.2019, 9[DOI]
74. Gao H, "PD-L1 regulates tumo-rigenesis and autophagy of ovarian cancer by activating mTORC signaling", Biosci Rep, 39, pp.BSR2019104~ (2019)
75. Huttlin EL, "The BioPlex network : a systematic exploration of the human interac-tome", Cell, 162, pp.425~440 (2015)
76. Escors D, "The intracellular signalosome of PD-L1 in cancer cells", Signal Transduct Target Ther, 3, pp.26~ (2018)

관련 논문AI추천